Timeline:  

• September 2007 – Acquisition of CPD Business Evotec
• July 2007 – Aptuit introduces Aptuit IVRS powered by Clarix
• June 2007 – First integrated drug delivery contract with Danube Pharmaceuticals
• June 2007 – Laurus joint venture announced
  Aptuit Laurus launched
• May 2007 – Clinicopia 4.1 launched
• February 2007 – $100 Million internal investment/EaglePicher & SSCI acquisitions close
• October 2006 – Clinicopia labeling launched
• May 2006 – Pharma Consulting, Inc. acquisition close/Aptuit Consulting launched
• April 2006 –$750M in private equity secured
• March 2006 – InfoPro acquisition close/Aptuit Informatics launched
• November 2005 – InfoPro acquisition agreement announced
• October 2005 – Quintiles EDP acquisition close
• September 2005 – Almedica acquisition close
• August 2005 – Almedica acquisition agreement announced
• July 2005 – Quintiles EDP acquisition agreement announced
• July 2005 – GPD becomes Aptuit
• January 2005 – Initial funding from Welsh, Carson, Anderson, & Stowe
• December 2004 – GPD founded by Michael Griffith, Frank Wright and Jon Tropsa

Founding Aptuit

Aptuit is a company on a mission - to streamline and support the drug development process for biotechnology and pharmaceutical innovators. Originally named Global Pharmaceutical Development, Inc., the company was founded in late 2004 by Michael Griffith, Frank Wright, and Jon Tropsa, three entrepreneurial industry veterans who saw the need to dramatically improve the research-to-commercialization process to keep up with the continuing evolution of the industry. Mike, Frank, and Jon had extensive market experience and a successful track record in building a similar, highly successful company through acquisitions and investment.

 

The founding team observed that there has been an explosion of new technologies that revolutionized early stage development. In addition, clinical trials have also taken on a global nature, encompassing patient groups and facilities in multiple countries. However, the actual research-to-commercialization process has not yet evolved to stay in tune with these innovations. These factors create the need to completely reengineer the industry’s approach to drug development, as well as revisit traditional management ideas to eliminate repetition, rework, and review.

 

Aptuit’s revolutionary business model is the realization of the founding team’s long-held belief in the commercial and technical value of innovation, and directly addresses the major inefficiencies and complexities that make the current process prolonged and expensive. Aptuit targeted and acquired the best technologies and expertise in the drug development sector, resulting in a business that offers a modular approach with a truly integrated service offering across the entire drug development continuum. Customers can select distinctive parts of the mix, or an end-to-end solution.

 

The goal is simple: to cut timelines, maintain quality, and reduce the overall cost of commercialization.

 

Building Aptuit

Although Aptuit was founded in 2004, the core operations within the Aptuit business units have more than 30 years of history of providing continuous quality service to pharmaceutical, biopharmaceutical, and CRO partners around the world. This expertise results from a number of strategic acquisitions and creative development as the founders targeted the best talent, facilities, and technology in the industry. 

 

In early 2005, the founders secured significant funding from Welsh, Carson, Anderson & Stowe, one of the world’s top private equity firms. Over the next year, Aptuit completed four significant acquisitions (Quintiles Early Development and Packaging business units, Almedica International, InfoPro Solutions, and Pharma Consulting Inc.), firmly establishing the company as a leading player in the provision of drug development services and the largest global provider of clinical packaging and logistics services by capacity. The company grew from just a handful of employees, to a global presence with more than 1,800 employees, 12 global facilities, and resources reaching 70 countries.

 

Aptuit made a significant internal investment in the newly acquired business units, hiring top-tier industry experts to offer clients seamless and horizontal project management and working to build the industry’s first seamless IT system that allows customers to access their data anywhere in the world, in real time.

 

The result is a series of overlapping service modules that stretch across the entire drug development continuum. Customers can choose from a complete offering that can successfully take them from discovery to commercialization. This offering includes:   

• Active pharmaceutical ingredient development
• Drug substance development and supply
• Drug metabolism pharmacokinetics
• Toxicology
• Bioanalysis
• Informatics
• Pharmaceutics
• Clinical packaging and logistics

Aptuit is truly engineering a better drug development process.